298 related articles for article (PubMed ID: 24711662)
1. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Roccaro AM; Sacco A; Jimenez C; Maiso P; Moschetta M; Mishima Y; Aljawai Y; Sahin I; Kuhne M; Cardarelli P; Cohen L; San Miguel JF; Garcia-Sanz R; Ghobrial IM
Blood; 2014 Jun; 123(26):4120-31. PubMed ID: 24711662
[TBL] [Abstract][Full Text] [Related]
2. It is time to move forward with Waldenström!
Efebera YA
Blood; 2014 Jun; 123(26):4007-8. PubMed ID: 24970926
[TBL] [Abstract][Full Text] [Related]
3. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
4. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
5. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Magierowicz M; Tomowiak C; Leleu X; Poulain S
Hematol Oncol Clin North Am; 2018 Oct; 32(5):753-763. PubMed ID: 30190015
[TBL] [Abstract][Full Text] [Related]
6. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.
Hiemcke-Jiwa LS; Leguit RJ; Jiwa NM; Huibers MMH; Minnema MC
Br J Haematol; 2019 Jun; 185(5):966-969. PubMed ID: 30408147
[No Abstract] [Full Text] [Related]
9. CXCR4-targeted PET imaging using
Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
[No Abstract] [Full Text] [Related]
10. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
11. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 in Waldenström's Macroglobulinema: chances and challenges.
Kaiser LM; Hunter ZR; Treon SP; Buske C
Leukemia; 2021 Feb; 35(2):333-345. PubMed ID: 33273682
[TBL] [Abstract][Full Text] [Related]
13. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
14. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
15. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
18. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
19. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
20. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
